GOAL To bring at least 20 new molecules into clinical development. Status: We added seven new molecular entities into early-stage development in 2006, including three small molecules via collaborations. »
GOAL To bring at least 15 major new products or indications to the market. Status: We received approval for one new product and seven additional indications for existing products in 2006. »
GOAL To achieve a compound annual non-GAAP earn- ings per share growth rate of 25%. Status: Our non-GAAP earnings per share growth rate for 2006 was 74%. »
GOAL To achieve cumulative free cash flow of US$12bn. Status: Our free cash flow as of 31 December 2006 was nearly $1bn. »
GOAL To become the number one US oncology company in sales. Status: We achieved the ranking of number one in US oncology sales in the first quarter of 2006 and will strive to maintain that ranking in the future.